ImmuPharma Shares Rise on Lupus Phase 3 Studies Preparations
May 04 2022 - 4:19AM
Dow Jones News
By Michael Susin
Shares in ImmuPharma PLC rose on Wednesday after the company
said that its lupus treatment Lupuzor is on final preparations to
enter into a Phase 3 clinical trial.
Shares at 0727 GMT were up 0.6 pence, or 8.7%, at 7.0 pence.
The London-listed drug discovery and development company said
its U.S. partner Avion Pharmaceuticals has requested final guidance
from the U.S. Food & Drug Administration to commence the last
stage clinical studies.
The company said Phase 1 studies required by the FDA showed that
the treatment "was safe and well tolerated across all doses and in
all subjects".
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
May 04, 2022 04:04 ET (08:04 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024
